Navigation Links
Onyx Pharmaceuticals Announces Positive Top-Line Carfilzomib Data From Phase 2b Study
Date:7/26/2010

events were observed.

The company has also initiated a large randomized international Phase 3 clinical trial, known as the ASPIRE trial, studying the combination of lenalidomide and low dose dexamethasone with or without carfilzomib in patients with relapsed multiple myeloma. The company has an agreement with the U.S. FDA on a Special Protocol Assessment (SPA) and received Scientific Advice from the European Medicines Agency (EMA) on the design and planned analysis for the ASPIRE trial.  A second Phase 3 clinical trial, known as the FOCUS trial, is planned to evaluate carfilzomib in patients with advanced myeloma and serve as the basis for a European registration. Carfilzomib is also being studied in advanced solid tumors.

About Multiple Myeloma

Multiple myeloma is the second most common hematologic cancer and results from an abnormality of plasma cells, usually in the bone marrow.  In the United States, more than 50,000 people are living with multiple myeloma and approximately 20,000 new cases are diagnosed annually.(iii) Worldwide, more than 180,000 people are living with multiple myeloma and approximately 86,000 new cases are diagnosed annually.(iv)

About Onyx Pharmaceuticals, Inc.

Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer. The company, in collaboration with Bayer HealthCare Pharmaceuticals, Inc., is developing and marketing Nexavar® (sorafenib) tablets, a small molecule drug that is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, Nexavar is being investigated in several ongoing trials in a variety of tumor types. Beyond Nexavar, Onyx has established a development pipeline of anticancer compounds at various stages of clinical testing, including carfilzomib,
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Onyx Pharmaceuticals Announces a Teleconference and Webcast to Provide a Clinical Update on Carfilzomib
2. Alexza Pharmaceuticals Appoints Joseph L. Turner to Its Board of Directors
3. Poniard Pharmaceuticals Receives NASDAQ Deficiency Notice Related to Minimum Bid Price
4. Bayer HealthCare Pharmaceuticals Supports New Jersey Governors School in the Sciences at Drew University
5. Anadys Pharmaceuticals to Report Second Quarter 2010 Financial Results
6. Lotus Pharmaceuticals Terminates SEDA
7. Ampio Pharmaceuticals Announces Initiation of Phase II Clinical Trial of Optina™
8. China Yongxin Pharmaceuticals Inc. Announces the Expansion of Its Chain of Retail Stores to 110 Stores
9. Endo Pharmaceuticals to Announce Second Quarter 2010 Financial Results on July 30, 2010
10. Susquehanna Financial Group Hires Gary Nachman as Senior Analyst to Cover the Specialty Pharmaceuticals Sector
11. Endo Pharmaceuticals Completes Acquisition of HealthTronics, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... July 24, 2014   AcelRx Pharmaceuticals, Inc.  (Nasdaq: ... on the development and commercialization of innovative therapies for ... the PDUFA date for Zalviso remains July 27, 2014.  ... circulated online stating the Food and Drug Administration (FDA) ... has been no notification to the company from the ...
(Date:7/24/2014)... Wis. , July 24, 2014  Restore ... specialty and compounded pharmaceuticals, announced that it is ... information unique to each individual based upon their ... possible by understanding the interaction between a patient,s ... "We,re very excited to provide this new ...
(Date:7/24/2014)... 2014  Uroplasty, Inc. (NASDAQ: UPI ), ... markets innovative proprietary products to treat voiding dysfunctions, ... first quarter ended June 30, 2014.  Global ... System grew 19% to $4.1 million, as compared ... the prior year.  Total revenue for the fiscal ...
Breaking Medicine Technology:AcelRx Pharmaceuticals Confirms July 27, 2014 PDUFA Date for Zalviso 2Restore Health Launches Pharmacogenetic Testing, Enhancing Its Suite of Personalized Medicine Goods and Services 2Restore Health Launches Pharmacogenetic Testing, Enhancing Its Suite of Personalized Medicine Goods and Services 3Uroplasty Reports Fiscal First Quarter Results 2Uroplasty Reports Fiscal First Quarter Results 3Uroplasty Reports Fiscal First Quarter Results 4Uroplasty Reports Fiscal First Quarter Results 5Uroplasty Reports Fiscal First Quarter Results 6Uroplasty Reports Fiscal First Quarter Results 7Uroplasty Reports Fiscal First Quarter Results 8Uroplasty Reports Fiscal First Quarter Results 9Uroplasty Reports Fiscal First Quarter Results 10Uroplasty Reports Fiscal First Quarter Results 11
... Pa., April 23 Wyeth,Pharmaceuticals, a division of ... it,is withdrawing its application for an extension to ... sought approval,of TYGACIL for the treatment of community-acquired ... of the Committee for Medicinal,Products for Human Use ...
... an Investigational Drug for Duchenne/Becker ... Muscular Dystrophy, ... announced the initiation of an international pivotal trial of,PTC124 in patients ... objective of this registration-directed,Phase 2b trial is to demonstrate the efficacy ...
Cached Medicine Technology:More Clinical Data Required to Support European Approval of CAP Indication for TYGACIL 2More Clinical Data Required to Support European Approval of CAP Indication for TYGACIL 3More Clinical Data Required to Support European Approval of CAP Indication for TYGACIL 4More Clinical Data Required to Support European Approval of CAP Indication for TYGACIL 5PTC Therapeutics Announces Initiation of Phase 2b Registration-Directed Clinical Trial of PTC124 in Duchenne/Becker Muscular Dystrophy 2PTC Therapeutics Announces Initiation of Phase 2b Registration-Directed Clinical Trial of PTC124 in Duchenne/Becker Muscular Dystrophy 3PTC Therapeutics Announces Initiation of Phase 2b Registration-Directed Clinical Trial of PTC124 in Duchenne/Becker Muscular Dystrophy 4PTC Therapeutics Announces Initiation of Phase 2b Registration-Directed Clinical Trial of PTC124 in Duchenne/Becker Muscular Dystrophy 5
(Date:7/25/2014)... and desires in initial romantic encounters determine the fate ... those initial "sparks" necessary to fuel sexual desire and ... a desirable trait for both men and women on ... the other person? Do men perceive responsive women as ... women,s perceptions of men? A study published in ...
(Date:7/25/2014)... San Mateo, CA (PRWEB) July 25, 2014 ... in an upcoming episode of Innovations with Ed Begley ... Dates and show times TBA. , For more than ... and the Bay Area community through its residential alcohol ... Innovations will educate on Project Ninety's humble idea and ...
(Date:7/25/2014)... July 25, 2014 Home Care Assistance ... provider of non-medical, in-home senior care, is weighing in ... be supporting senior-led projects in Alberta through their New ... for Seniors Program is a federal grants and contributions ... who make a difference in the lives of others ...
(Date:7/25/2014)... Ca (PRWEB) July 25, 2014 The ... with their Anniversary Futon Sale. The Futon Shop has been ... pop shop, which has grown from a few handmade futon ... 33 different kinds of futon mattresses. , The Futon ... the beginning and the desire to sleep on natural fibers ...
(Date:7/25/2014)... ZeptoMetrix™ Corporation (ZMC), an industry leader ... and services for infectious disease diagnostic development, is ... Multimarker Controls - MDZ001 . , An ... marked, unassayed external run control intended for use ... Multimarker Controls - MDZ001 has been specifically designed ...
Breaking Medicine News(10 mins):Health News:Why do men prefer nice women? 2Health News:Why do men prefer nice women? 3Health News:Project Ninety to be Featured on Innovations with Ed Begley, Jr. 2Health News:Project Ninety to be Featured on Innovations with Ed Begley, Jr. 3Health News:Home Care Assistance – Halton/Peel Region Weighs in on Alberta Communities Receiving Funding to Support Seniors and Senior Caregivers 2Health News:Home Care Assistance – Halton/Peel Region Weighs in on Alberta Communities Receiving Funding to Support Seniors and Senior Caregivers 3Health News:Organic Mattress Manufacturer Celebrates 38 Years Of Being In Business 2Health News:Organic Mattress Manufacturer Celebrates 38 Years Of Being In Business 3Health News:ZeptoMetrix™ Corporation (ZMC) Releases FDA Class 1 Exempt, IVD and CE Labeled NATtrol™ RP Multimarker Controls 2
... protecting children from flu if they included both strains of ... has found. "Adding a second influenza B virus strain ... guesswork out of strain selection and help improve the vaccine,s ... and director of the Center for Vaccine Development at Saint ...
... ... Wigix Inc.’s subsidiary, ddku.com, affording it an end to end marketing platform in China. ... Oakland, CA ... has acquired a Shanghai-based business process outsourcing company, Mag2U, to enhance DDKU’s growing internet ...
... testing, experts say , TUESDAY, April 6 (HealthDay News) -- ... have a genetic mutation that boosts their risk for the ... breast than are women who don,t have the genetic mutations, ... these women, who carry a mutation in the BRCA1 and ...
... Today, the Interactive Autism Network (IAN), www.ianproject.org, the ... of the Grandparents of Children with Autism Spectrum ... who participated were the first to raise concerns ... 2007, the IAN Project has helped to accelerate ...
... Indianapolis, 6 April, 2010 The global nursing shortage is ... schools and to a phenomenon known as nurse migration, where ... response, the International Council of Nurses (ICN) and the Honor ... The Elsevier Foundation, will conduct the Global Summit on Nurse ...
... April 2010 - Attention-deficit/hyperactivity disorder (ADHD) is one of ... adolescents. Children with ADHD are excessively restless, impulsive, and ... Problems inhibiting behavior are a common theme for ADHD ... medications, behavioral approaches or a combination of the two. ...
Cached Medicine News:Health News:Building a better flu vaccine: Add second strain of influenza B 2Health News:Wigix Acquires Mag2U, A Leading Business Process Outsourcing Company 2Health News:Wigix Acquires Mag2U, A Leading Business Process Outsourcing Company 3Health News:Gene Mutations Up Risk for Cancer in Opposite Breast 2Health News:Gene Mutations Up Risk for Cancer in Opposite Breast 3Health News:New survey finds grandparents play key role in lives of children with autism 2Health News:New survey finds grandparents play key role in lives of children with autism 3Health News:International summit seeks solutions to global shortage of nursing faculty 2Health News:Synergy between behavioral and pharmacologic interventions for ADHD 2
The uncemented hip joint prosthesis system....
The cemented hip joint prosthesis system....
The cemented hip joint prosthesis system....
The Quatroloc primary hip system offers 35 primary stems to fit almost all femurs for primary hip arthroplasty....
Medicine Products: